
Allovir Inc (KLRS) Stock Forecast & Price Target
Allovir Inc (KLRS) Analyst Ratings
Bulls say
Kalaris Therapeutics is poised for success with their novel anti-VEGF drug, TH103, which has shown promising results in early clinical data for wet macular degeneration and has a unique mechanism of action. With the US market for this condition estimated at over $15B, the company has great potential for revenue growth and addressing an unmet need. However, there are risks associated with the development and commercialization of the drug that could impact its success.
Bears say
Kalaris Therapeutics is entering a highly competitive market with their TH103 drug, and while potential dosing advantages and a unique binding profile may give it some edge, further research is needed to establish its efficacy. Additionally, other major players in the field, such as Eylea and Lucentis, already have established drugs and strong market presence. KLRS will need to successfully navigate these challenges and effectively market their drug to see significant financial success.
This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.
Allovir Inc (KLRS) Analyst Forecast & Price Prediction
Start investing in Allovir Inc (KLRS)
Order type
Buy in
Order amount
Est. shares
0 shares